Pentraxin 3 and complement cascade activation in the failure of arteriovenous fistula

Castellano, Giuseppe; Vittorio, Angela Di; Dalfino, Giuseppe; Loverre, Antonia; Marrone, Daniela; Simone, Simona; Schena, Francesco Paolo; Pertosa, Giovanni; Grandaliano, Giuseppe

doi:10.1016/j.atherosclerosis.2009.08.044

Cited by 20 publications

(18 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In other areas, complement system and PTX3 might also have a significant correlation. For example, a previous study had revealed a close association between PTX3 deposition and complement activation at the endothelial cell level in failed arteriovenous fistula (Castellano et al 2010). Therefore, we explored the change of complement proteins in CRC patients in the study, and preliminarily discovered the activation of complement system in patients.…”

Section: Discussionmentioning

confidence: 99%

Increased Plasma Levels of Pentraxin 3 Are Associated with Poor Prognosis of Colorectal Carcinoma Patients

Zhang

Wang

Niu

2016

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Colorectal carcinoma (CRC) is one of the most common cancers globally. It is essential to identify a prognostic predictor for CRC. Pentraxin 3 (PTX3) is a glycoprotein that is secreted by a variety of human cells. It plays an important role in inflammation and immune regulation. Increasing evidence reveals that elevated PTX3 expression is related to poor prognosis in various cancers. The aim of the study was to determine the usefulness of plasma PTX3 level as a prognostic predictor in CRC. Total 184 CRC patients and 216 controls were included. Plasma levels of PTX3 were determined using Enzyme-linked immunosorbent assays. On admission, plasma PTX3 levels in CRC patients were higher than those in controls (11.8 ± 2.5 ng/ml vs. 3.1 ± 0.9 ng/ml, P < 0.001). After resection, plasma PTX3 levels in patients were decreased (6.0 ± 1.4 ng/ml, P = 0.007), and were elevated at the time of relapse (10.8 ± 2.8 ng/ml, P < 0.001). During the 60-month follow-up period, 108 patients suffered from relapse. Plasma PTX3 levels of ≥ 12 ng/ml on admission were associated with relapse (OR: 3.11, 95% CI: 1.74 ~ 6.29), and tumor-free survival rate in those patients with plasma PTX3 levels of ≥ 12 ng/ml was lower than that in other patients (P = 0.001). Furthermore, plasma PTX3 levels on admission showed positive linear correlations with plasma complement 3, 4 and 5b9 levels (P < 0.001, P < 0.001, P < 0.001). Therefore, we propose that PTX3 is an independent prognostic indicator in CRC.

show abstract

Section: Discussionmentioning

confidence: 99%

Increased Plasma Levels of Pentraxin 3 Are Associated with Poor Prognosis of Colorectal Carcinoma Patients

Zhang

Wang

Niu

2016

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

show abstract

“…Tissue damage and organ complications are related to vasculitis, which is characteristic of the disease [1][2][3]. Inflammatory lesions to blood vessels mainly result from prolonged activation of endothelial cells, continuously exposed to autoantibodies and circulating immune complexes [4]. It should be noted that systemic vasculitis in SLE is considered a pro-atherogenic state and hence an important prognostic factor [5].…”

Section: Introductionmentioning

confidence: 99%

“…It has been documented that PTX3 is locally synthesized at sites of active vasculitis [4,12,13]. The synthesis takes place in endothelial and smooth muscle cells as well as granulocytes [12][13][14].…”

Section: Introductionmentioning

confidence: 99%

Pentraxin 3 as a biomarker of local inflammatory response to vascular injury in systemic lupus erythematosus

Cieślik

Hrycek

2014

Autoimmunity

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is an autoimmune disorder with organ injury related to vasculitis. Inflammation of blood vessels results from auto-immunological activation of endothelial cells. The pentraxin 3 (PTX3), might act as an indicator of vasculitides in many diseases. The aim of this study was to determine whether PTX3 might be useful as a marker of vascular injury in SLE. This study was carried out in a group of 56 SLE women, and in the 28 female volunteers control group. All participants' plasma and serum samples were collected to estimate concentrations (ELISA) of PTX3, soluble thrombomodulin, soluble E-selectin (sE-selectin), soluble P-selectin (sP-selectin), soluble form of vascular cell adhesion molecule 1 (sVCAM-1), soluble inter-cellular adhesion molecule-1 (sICAM-1), soluble platelet endothelial cell adhesion molecule 1, monocyte chemotactic protein-1 (MCP-1) and von Willebrand factor (vWF) activity. Anthropometric, demographic and lifestyle characteristics of SLE patients were also performed. The SLE patients had higher PTX3, vWF, MCP-1, sE-selectin and sVCAM-1 levels than the controls (1.82 ± 1.56 ng/mL, 237 ± 101%, 70.05 ± 18.31 ng/mL, 111.16 ± 49.15 ng/mL and 978.78 ± 462.35 ng/mL vs. 0.86 ± 0.40 ng/mL, 138 ± 43%, 58.56 ± 13.91 ng/mL, 66.04 ± 27.18 ng/mL and 499.07 ± 125.67 ng/mL, respectively). The independent factors affecting PTX3 expression included Systemic Lupus Erythematosus Disease Activity Index, prednisone dose and anemia severity. Moreover, the PTX3 areas under the curve-receiver operating characteristics curves 0.717 ± 0.056 with cut-off level of 1.96 ng/mL was comparable to vWF, MCP-1, sE-selectin, sP-selectin and sICAM-1. PTX3 and sVCAM-1 were the only factors related to SLE activity. Other vascular injury indicators associated with PTX3 were vWF and sVCAM-1. In conclusion, PTX3 concentrations in SLE patients might serve as a indicator of the activation/dysfunction of vascular endothelium.

show abstract

“…PTX3 can bind to the complement component c1q, extra cellular matrix, TNF-α, microorganisms and modulate innate immunity as an independent sensitive inflammatory marker [9,10].…”

Section: Introductionmentioning

confidence: 99%

Association of the long pentraxin PTX3 gene polymorphism (rs3816527) with migraine in an Iranian population

Zandifar

Iraji

Taheriun

et al. 2015

Journal of the Neurological Sciences

View full text Add to dashboard Cite

Pentraxin 3 and complement cascade activation in the failure of arteriovenous fistula

Cited by 20 publications

References 31 publications

Increased Plasma Levels of Pentraxin 3 Are Associated with Poor Prognosis of Colorectal Carcinoma Patients

Increased Plasma Levels of Pentraxin 3 Are Associated with Poor Prognosis of Colorectal Carcinoma Patients

Pentraxin 3 as a biomarker of local inflammatory response to vascular injury in systemic lupus erythematosus

Association of the long pentraxin PTX3 gene polymorphism (rs3816527) with migraine in an Iranian population

Contact Info

Product

Resources

About